PharmaShots | Incisive News in 3 Shots

Subscribe Now

Peripheral T-Cell Lymphomas

Seattle Genetics' Adcetris (brentuximab vedotin) Receives FDA's Breakthrough Designation for Frontline Peripheral T-Cell Lymphomas

Seattle Genetics' Adcetris (brentuximab vedotin) Receives FDA's Breakthrough Designation for Frontline Peripheral T-Cell Lymphomas

November 15, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us